Published in Cancer Weekly, May 19th, 2009
Under the agreement, the two companies will develop diagnostic products that incorporate Fujirebio Diagnostics' cancer biomarkers for use on BD's multiplex testing platform. The initial products will be directed to the ovarian cancer biomarker, HE4, which is FDA-cleared for monitoring the progression or recurrence of epithelial ovarian cancer. Fujirebio Diagnostics also grants BD, through its BD Diagnostics - TriPath platform, access to its other cancer biomarkers for inclusion in future...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.